<DOC>
	<DOCNO>NCT00525759</DOCNO>
	<brief_summary>There clear preclinical vitro vivo evidence sequence dependent synergy chemotherapy agent zoledronic acid . The aim study investigate synergistic increase tumour cell apoptosis observe preclinical study occur patient . The hypothesis study may anti-tumour benefit sequential application chemotherapy agent follow zoledronic acid patient invasive breast cancer .</brief_summary>
	<brief_title>Investigating Biological Effects Addition Zoledronic Acid Pre-operative Chemotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women histological diagnosis invasive breast cancer require neoadjuvant chemotherapy T2 tumour WHO Performance status 0,1 2 Must consent undergone core biopsy diagnosis breast cancer AND consent undergo additional core biopsy prior second cycle chemotherapy ( Day 5 +/ Day 21 ) Written inform consent Previous chemotherapy radiotherapy treat breast Evidence metastatic disease recurrent breast cancer previous malignancy ( exception ) Calculated creatinine clearance &lt; 40mls/min Prior treatment bisphosphonates last year know contraindication bisphosphonate therapy Concurrent tamoxifen aromatase inhibitor medication Pregnant lactate woman Cardiac dysfunction precludes use anthracycline chemotherapy Unwilling extra interim biopsy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Synergy</keyword>
	<keyword>Apoptosis</keyword>
</DOC>